Tag: pharma R&D

Partnering, Outsourcing and Alliances to Scale Modalities: Small Molecules, Biologics, ATMPs Partnering, Outsourcing and Alliances to Scale Modalities: Small Molecules, Biologics, ATMPs Introduction to Modalities in Pharmaceutical R&D The landscape of pharmaceutical research and development is evolving rapidly, driven by advancements in technology and changing regulatory environments. Modalities such as small molecules, biologics, and advanced…

Read More “Partnering, Outsourcing and Alliances to Scale Modalities: Small Molecules, Biologics, ATMPs” »

Common Pitfalls in Modalities: Small Molecules, Biologics, ATMPs—and How to Avoid Costly Rework Introduction to Modalities and Their Importance in Clinical Trials The contemporary landscape of pharmaceutical research and development is characterized by the increasing complexity of therapeutic modalities, including small molecules, biologics, and advanced therapy medicinal products (ATMPs). Each type presents unique challenges that…

Read More “Common Pitfalls in Modalities: Small Molecules, Biologics, ATMPs—and How to Avoid Costly Rework” »

Modalities: Small Molecules, Biologics, ATMPs: Strategic Playbook for Modern Pharma R&D In the rapidly evolving landscape of pharmaceutical research and development (R&D), understanding the different modalities used in drug development is crucial for professionals involved in clinical operations, regulatory affairs, medical affairs, and R&D. This article that follows serves as a strategic playbook, offering insights…

Read More “Modalities: Small Molecules, Biologics, ATMPs: Strategic Playbook for Modern Pharma R&D” »

How to Design Modalities: Small Molecules, Biologics, ATMPs That Accelerates Time-to-Proof-of-Concept How to Design Modalities: Small Molecules, Biologics, ATMPs That Accelerates Time-to-Proof-of-Concept The evolution of drug development paradigms necessitates a comprehensive understanding of the various modalities employed in clinical research. This tutorial aims to equip clinical operations, regulatory affairs, medical affairs, and R&D professionals with…

Read More “How to Design Modalities: Small Molecules, Biologics, ATMPs That Accelerates Time-to-Proof-of-Concept” »

Modalities: Small Molecules, Biologics, ATMPs in Practice: Case Studies, Workflows and Governance Models Modalities: Small Molecules, Biologics, ATMPs in Practice: Case Studies, Workflows and Governance Models As the pharmaceutical industry continues to evolve, the development of new therapeutic modalities and their integration into clinical trials presents both challenges and opportunities for clinical operations professionals. Understanding…

Read More “Modalities: Small Molecules, Biologics, ATMPs in Practice: Case Studies, Workflows and Governance Models” »

High-Impact Modalities: Small Molecules, Biologics, ATMPs Tactics That De-Risk Clinical Development High-Impact Modalities: Small Molecules, Biologics, ATMPs Tactics That De-Risk Clinical Development Introduction to High-Impact Modalities in Clinical Development The pharmaceutical landscape is increasingly characterized by complex therapeutic modalities, including small molecules, biologics, and Advanced Therapy Medicinal Products (ATMPs). As clinical trial professionals, understanding how…

Read More “High-Impact Modalities: Small Molecules, Biologics, ATMPs Tactics That De-Risk Clinical Development” »

Integrating Modalities: Small Molecules, Biologics, ATMPs With Clinical Development, CMC and Market Access The pharmaceutical industry is witnessing a significant transformation in the development of therapeutics, driven by advancements in our understanding of disease biology and the emergence of new drug modalities. This guide aims to provide a comprehensive overview of integrating small molecules, biologics,…

Read More “Integrating Modalities: Small Molecules, Biologics, ATMPs With Clinical Development, CMC and Market Access” »